WebThe Centre of Excellence in Severe Asthma convened three forums between 2015 and 2024, hosting experts from Australia, New Zealand and the UK. The forums were … WebDec 3, 2024 · Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. The disease affects more than 300 million individuals worldwide, and …
Targeting treatable traits in severe asthma: a randomised …
WebApr 13, 2024 · Enter INCA, a digital health device developed at RCSI University of Medicine and Health Sciences and Trinity College Dublin. The INCA device attaches to an asthma sufferer’s inhaler and measures when and how well they use it to deliver the corticosteroid medicines into their airways. With this kind of information, doctors are on a more solid ... WebAug 2, 2024 · Save-the-date for the upcoming Centre of Excellence in Severe Asthma Annual Research Day. If you are interested in attending, please RSVP to [email protected]. The programme will include an all-day research meeting and a public evening symposium, presented by local researchers and experts from … dr jesus frausto
Targeting Treatable Traits in Severe Asthma: A Randomised …
Web16 hours ago · Participants who received a bivalent mRNA booster vaccine dose had lower rates of hospitalisation due to COVID-19 than participants who did not receive a bivalent … WebDec 17, 2024 · The approval of Tezspire is long-awaited positive news for the asthma community. For the first time, many people living with severe asthma have the opportunity to receive treatment regardless of the cause of their inflammation.”. Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: “Today’s … WebProf. Peter Gibson (University of Newcastle, Hunter Medical Research Institute, John Hunter Hospital) is a respiratory physician and clinical scientist studying the disease mechanisms and treatment of severe asthma, chronic obstructive pulmonary disease (COPD), cough and other airway disorders. ramon jeremias